Page 51 - Read Online
P. 51

Page 667                                                Sooi et al. Cancer Drug Resist 2023;6:656-73  https://dx.doi.org/10.20517/cdr.2023.48

               Table 2. Trials looking at novel therapies in advanced prostate cancer
                Trial number Phase    Intervention arm(s)           Population         Outcome    Status
                CAR T
                NCT04227275 1  CART-PSMA-TGFβRDN            mCRPC after progression on 2 NHAs  DLT, safety  Active, not
                                                                                               recruiting
                NCT03089203 1  CART-PSMA-TGFβRDN            mCRPC after progression on ≥ 1   Safety  Active,
                                                            systemic therapy                   recruiting
                NCT04053062 1  LIGHT-PSMA-CART              mCRPC after progression on   Safety  Suspended
                                                            Abiraterone and chemotherapy
                NCT04249947 1  P-PSMA-101 CAR-T             mCRPC                    ORR, DLT,   Active, not
                                                                                     safety    recruiting
                NCT03873805 1  Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-  PSCA+ mCRPC       DLT, safety  Active,
                               expressing T-lymphocytes                                        recruiting
                NCT02744287 1/2  BPX-601 (PSCA-specific CAR-T cells)  PSCA+ mCRPC    DLT, safety  Active,
                                                                                               recruiting
                NCT03013712  1/2  EpCAM-specific CAR T Cells  EpCAM+ mCRPC           Safety    Unknown
                BiTE
                NCT04104607 1  CC-1 (PSMAxCD3)              mCRPC after progression on ≥ 3   Safety  Active,
                                                            systemic therapies                 recruiting
                NCT03792841 1  Acapatamab (PSMAxCD3)        mCRPC after progression on 1 NHA and  DLT, safety  Active, not
                                                            1 chemotherapy                     recruiting
                NCT01140373  1/2  HPN424 (PSMAxCD3)         mCRPC after progression on ≥ 2   ORR, DLT  Active, not
                                                            systemic therapies                 recruiting
                NCT03972657 1/2  REGN5678 (PSMAxCD28) + Cemiplimab  mCRPC after progression on ≥ 2   ORR, DLT,   Active,
                                                            systemic therapies       safety    recruiting
                NCT04221542 1  AMG 509 (STEAP1xCD3)         mCRPC after progression on 1 NHA and  DLT, safety  Active,
                                                            1 chemotherapy                     recruiting
                NCT03406858 2  HER2Bi-armed activated T cells   mCRPC                PFS       Active, not
                               (HER2xCD3) + Pembrolizumab                                      recruiting
               DLT: dose limiting toxicity; EpCAM: Epithelial cell adhesion molecule; mCRPC: metastatic castration-resistant prostate cancer; NHAs: novel
               hormonal agents; ORR: objective response rate; PFS: progression-free survival; PSCA: prostate stem cell antigen.






























                Figure 3. Bispecific T cell engager binding CD3 on T cell with PSMA on prostate cancer cell. BiTE: Bispecific T-cell engager; PSMA:
                prostate-specific membrane antigen.
   46   47   48   49   50   51   52   53   54   55   56